SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission Post author:Sam Post published:December 7, 2017 Post category:BioPharma No clinical trials are required for the NDA resubmission. Source: BioSpace You Might Also Like <b>President Trump</b> Tosses Tweet-Bomb at Drug Industry, Stocks Drop March 6, 2017 AcelRx Stopped Cold: FDA Rejects NDA for Pain Drug Dsuvia (ARX-04) October 11, 2017 SpinalCyte, LLC Receives New Japanese Patent July 20, 2017
